Q3 FY26 results: revenue down about 28 percent, PAT falls 21 percent

Revenue declinedEmphasis of matterResults View source PDF Explain this filing

AAREYDRUGS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹68.00

prior close

₹66.75

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+2.9% vs market

On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.0

10m

+1.1

15m

+2.8

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+2.4-0.5+2.9

Next day

-2.6-2.0-0.6

-4.9-2.7-2.2

-0.8-1.7+1.0

+3.6-1.4+5.0

+4.4-2.8+7.2

+17.7-2.8+20.6

15d

+5.4-8.4+13.8

+1.4-9.1+10.5

+5.3-4.0+9.4

+30.1+2.6+27.5

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarey Drugs Q3 FY26 revenue from operations fell to Rs 96.43 crore from Rs 133.79 crore YoY, a drop of about 28 percent. Nine-month revenue slipped 23 percent to Rs 282.80 crore from Rs 365.84 crore. Q3 PAT declined to Rs 57 lakh from Rs 72 lakh, with 9M PAT at Rs 2.96 crore versus Rs 3.55 crore. EPS for the quarter was Rs 0.20. The auditor gave an unqualified review but drew attention to capital assets not yet in use, so no depreciation was charged on them yet.

Likely market impact

Weak quarter with falling revenue and profits; flag on undepreciated capital assets hints at upcoming capacity addition.